^
    Back
    Association details:
    Biomarker:BRAF mutation
    Cancer:Melanoma
    Drug:SCH772984 (ERK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Mol Cancer
    Title:

    Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

    Excerpt:
    SCH772984 is highly active amongst BRAF-mutant, NRAS-mutant, double mutant and double wild-type melanoma cell lines, and this drug potently inhibited some lines with innate resistance or acquired resistance to vemurafenib.
    DOI:
    10.1186/1476-4598-13-194
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Cancer Discov
    Title:

    Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors

    Excerpt:
    Treatment of BRAF-mutant LOX melanoma xenografts with SCH772984 (50 mg/kg twice daily) led to 98% tumor regression
    DOI:
    10.1158/2159-8290.CD-13-0070